Home › Liver Cancer (Hepatocellular Carcinoma) › NCT03686709

Y90 Radioembolization Dose Delivery and Radiation Exposure Assessment

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* All patients undergoing Y90 radioembolization therapy with SIR-Spheres or TheraSpheres are eligible to participate in this study
* Must be able to schedule and tolerate additional PET/CT imaging following therapy
* Must be able to tolerate additional blood draws before, during, and after the radioembolization therapy procedure.

Exclusion Criteria:

* Patients that are not candidates for Y90 radioembolization therapy
* Patients that cannot tolerate additional imaging procedures following therapy
* Patients that cannot tolerate the additional blood draws required for this study
* Patients whose schedule does not allow them to remain at the hospital for the additional PET/CT imaging study

About the study

The objective of this study is to examine critical aspects of radiation exposure, dose delivery, and systemic yttrium-90 (Y90) exposure related to the infusion of Y90 microspheres for treatment of hepatocellular carcinoma (HCC) and other metastatic liver disease.

What is being tested

• Post therapy PET/CT Imaging (diagnostic test)

Sponsor: University of Tennessee · Participants: 20 · Started: Jun 19, 2018

Contact the study team

• Dustin Osborne, PhD · Phone: 8653058264
• Shelley Acuff · Phone: 8653056312

Official record on ClinicalTrials.gov — NCT03686709

Locations in the U.S.

Conditions

• Liver Cancer (Hepatocellular Carcinoma)

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.